References:

• 1.
  Local SMPC Empagliflozin (Summary of Product Characteristics). July 2023.
• 2.
  Zinman B, Wanner C, Lachin J, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. (ΕMPA-REG OUTCOME results and the publication's Supplementary Appendix for certain baseline characteristics).
• 3.
  Fitchett D, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J Am Coll Cardiol. 2018;71(3):364-367.
• 4.
  Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease: Survival estimates from the EMPA-REG OUTCOME trial. Circulation. 2018;138:1599-1601.